Literature DB >> 19201454

Genetic diversity of RANTES gene promoter and susceptibility to coronary artery disease and restenosis after percutaneous coronary intervention.

Konstantina Vogiatzi1, Vassilis Voudris, Stavros Apostolakis, Georgios E Kochiadakis, Sofia Thomopoulou, Apostolos Zaravinos, Demetrios A Spandidos.   

Abstract

Regulated on activation, normal T cell expressed and secreted (RANTES) gene promoter is a regulatory region and a site of notable genetic diversity. In order to explore a possible interaction between RANTES promoter genetic diversity and susceptibility to coronary artery disease (CAD) and in stent restenosis (ISR), we initially sequenced a locus extending from -516 to 40 covering the entire region of the RANTES promoter in 100 subjects randomly selected from our cohort. Four single nucleotide polymorphisms (SNPs) were identified: -403G/A, -256G/A, -109C/T and -28C/G. The frequency of the -109C/T and -256G/A variations was <0.01, and was considered to be of limited significance. The frequency of the -403G/A and -28C/G polymorphisms was evaluated in the entire sample, which consisted of 118 patients subjected to percutaneous coronary intervention (PCI) without ISR on angiographic re-evaluation (no IRS group), 74 CAD patients with ISR on angiographic re-evaluation (IRS group) and 146 controls without angiographic evidence of CAD (no CAD group). No association was established between the RANTES promoter genotype and ISR. A genotype-phenotype interaction was observed between the -403G/A polymorphism and CAD. The -403A homozygotes were significantly more common in the CAD group than in the controls. The severity of CAD among case subjects, expressed as the mean number of diseased vessels, was significantly higher among -403A homozygotes as compared to wild-type homozygotes and heterozygotes. In conclusion, the RANTES -403A allele was associated with the presence and severity of CAD independently of conventional cardiovascular risk factors. The RANTES promoter genotype did not influence susceptibility to ISR in patients subjected to PCI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19201454     DOI: 10.1016/j.thromres.2008.12.043

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  10 in total

1.  Association of circulating levels of RANTES and -403G/A promoter polymorphism to acute heart failure after STEMI and to cardiogenic shock.

Authors:  Jolana Lipkova; Jiri Parenica; Kamil Duris; Katerina Helanova; Josef Tomandl; Lenka Kubkova; Anna Vasku; Monika Goldbergova Pavkova
Journal:  Clin Exp Med       Date:  2014-06-17       Impact factor: 3.984

Review 2.  Chemokine receptor CCR5: from AIDS to atherosclerosis.

Authors:  K L Jones; J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

3.  Assessment of genetic diversity in IL-6 and RANTES promoters and their level in Saudi coronary artery disease patients.

Authors:  Nasimudeen R Jabir; Chelapram K Firoz; Mohammad A Kamal; Ghazi A Damanhouri; Mohammed Nabil Alama; Anas S Alzahrani; Hussein A Almehdar; Shams Tabrez
Journal:  J Clin Lab Anal       Date:  2016-11-09       Impact factor: 2.352

Review 4.  Genetics of coronary artery disease and myocardial infarction.

Authors:  Xuming Dai; Szymon Wiernek; James P Evans; Marschall S Runge
Journal:  World J Cardiol       Date:  2016-01-26

5.  Chemokines CCL3/MIP1α, CCL5/RANTES and CCL18/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes.

Authors:  Saskia C A de Jager; Brenda W C Bongaerts; Michael Weber; Adriaan O Kraaijeveld; Mat Rousch; Stefanie Dimmeler; Marja P van Dieijen-Visser; Kitty B J M Cleutjens; Patty J Nelemans; Theo J C van Berkel; Erik A L Biessen
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

6.  Protein targets of inflammatory serine proteases and cardiovascular disease.

Authors:  Ram Sharony; Pey-Jen Yu; Joy Park; Aubrey C Galloway; Paolo Mignatti; Giuseppe Pintucci
Journal:  J Inflamm (Lond)       Date:  2010-08-30       Impact factor: 4.981

7.  RANTES/CCL5 and risk for coronary events: results from the MONICA/KORA Augsburg case-cohort, Athero-Express and CARDIoGRAM studies.

Authors:  Christian Herder; Wouter Peeters; Thomas Illig; Jens Baumert; Dominique P V de Kleijn; Frans L Moll; Ulrike Poschen; Norman Klopp; Martina Müller-Nurasyid; Michael Roden; Michael Preuss; Mahir Karakas; Christa Meisinger; Barbara Thorand; Gerard Pasterkamp; Wolfgang Koenig; Themistocles L Assimes; Panos Deloukas; Jeanette Erdmann; Hilma Holm; Sekar Kathiresan; Inke R König; Ruth McPherson; Muredach P Reilly; Robert Roberts; Nilesh J Samani; Heribert Schunkert; Alexandre F R Stewart
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

8.  Association of CCL5 rs2107538, and CCL2 rs3760396 Gene Polymorphisms with the Risk of Cardiovascular Disease.

Authors:  Naser Mohtavinejad; Alireza Nakhaee; Honey Harati; Nazila Gholipour; Yavar Mahmoodzade
Journal:  Iran J Public Health       Date:  2021-07       Impact factor: 1.429

9.  RANTES gene G-403A polymorphism and coronary artery disease: a meta analysis of observational studies.

Authors:  Jun Liu; Yan-Jun Jia; Xiao-Lin Li; Rui-Xa Xu; Cheng-Gang Zhu; Yuan-Lin Guo; Na-Qiong Wu; Jian-Jun Li
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

Review 10.  Chemokine Receptor 5, a Double-Edged Sword in Metabolic Syndrome and Cardiovascular Disease.

Authors:  Zhongwen Zhang; Qiannan Wang; Jinming Yao; Xiaojun Zhou; Junyu Zhao; Xiaoqian Zhang; Jianjun Dong; Lin Liao
Journal:  Front Pharmacol       Date:  2020-03-03       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.